Effects of blood group types on risk of infection, disease severity, and mortality in COVID-19 patients
Abstract
Aim: COVID-19 is an epidemic communicable disease that has been declared as a pandemic caused by severe acute respiratory syndrome coronavirus 2. Clinical studies have demonstrated that advanced age and comorbid conditions enhance the severity of the infection. The objective of this study was to examine the of effects of blood group types on risk of infection, disease severity, and mortality in COVID-19 patients.
Material and Method: Included in this study were 1618 patients who had been diagnosed with PCR confirmed COVID-19 infection. The age, gender, blood type, disease severity, need for intensive care, and deaths of the patients were analyzed retrospectively. For the distribution of the blood types in a healthy population, statistics for the blood types of individuals in Ankara for 2020 were obtained from the Republic of Turkey Red Crescent Blood Services and used as a healthy control group for comparison with the data of the patients included in the study.
Results: Among the COVID-19 patients, blood type A was the most common type at a rate of 46.2%. This was followed by blood type O at a rate of 28.4%. The least common blood type was found to be type AB at a rate of 9%. When compared to the healthy population, blood type A was determined to be statistically significantly more common in COVID-19 infection (p=0.07,). In contrast, blood type O was determined to be less common when compared to the healthy population (p<0.001). No statistically significant differences were determined between the blood types and the risk of severe disease and mortality rate.
Conclusion: Based upon the results of the study, it can be hypothesized that blood group type O may be protective against the risk of contracting the disease and the development of severe infection, while blood group type A may be associated with an increased risk of contracting the disease. However, it was determined that there were no statistically significant associations of mortality and the development of severe disease with ABO blood types.
References
- World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. http: //www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
- Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9: 548-53.
- Jing W, Zhao S, Liu J, Liu M. ABO blood groups and hepatitis B virus infection: a systematic review and meta-analysis. BMJ Open 2020; 10: e034114.
- Franchini M, Favaloro EJ, Targher G, Lippi G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci 2012; 49: 137-49.
- Ibrahim-Kosta M, Bailly P, Silvy M, et al. ABO blood group, glycosyltransferase activity and risk of venous thromboembolism. Thromb Res 2020; 193: 31-5.
- Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.
- Dunne E, Qi QM, Shaqfeh ES, et al. Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood 2019; 133: 1371-7.
- Latz CA, DeCarlo C, Boitano L, et al. Blood type and outcomes in patients with COVID-19. Ann Hematol 2020; 99: 2113-8.
- Göker H, Aladağ Karakulak E, Demiroğlu H, et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci 2020; 50: 679-83.
- Aktimur SH, Sen A, Yazicioglu B, Gunes AK, Genc S. The assessment of the relationship between ABO blood groups and Covid-19 infection. UHOD - Int J Hematol Oncol 2020; 30: 121-5.
- Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun 2020; 11: 5761.
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, https: //apps.who.int/iris/handle/10665/330854 (Accessed on January 25, 2020).
- Ding X, Yu Y, Lu B, et al. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019. Clin Chem Lab Med 2020; 58: 1365-71
- Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus 2021; 19: 317-26.
- Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO blood types and COVID-19: spurious, anecdotal, or truly important relationships? a reasoned review of available data. Viruses 2021; 13: 160.
- Wu BB, Gu DZ, Yu JN, Yang J, Shen WQ. Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis. Infect Genet Evol 2020; 84: 104485.
- Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev 2021; 48: 100785.
- Domènech-Montoliu S, Puig-Barberà J, Pac-Sa MR, et al. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. Int J Environ Res Public Health 2021; 18: 10039.
- Ray JG, Schull MJ, Vermeulen MJ, Park AL. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study. Ann Intern Med 2021; 174: 308-15.
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844-7.
- Fogarty H, Townsend L, Ni Cheallaigh C, et al. More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol 2020; 189: 1060-1.
- McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2: e437-e45.
- Cooling L. Blood groups in infection and host susceptibility. Clin Microbiol Rev 2015; 28: 801-70.
- Guillon P, Clément M, Sébille V, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 2008; 18: 1085-93.
- Cheng Y, Cheng G, Chui CH, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005; 293: 1450-1.
- O'Sullivan JM, Ward S, Fogarty H, O'Donnell JS. More on 'Association between ABO blood groups and risk of SARS-CoV-2 pneumonia'. Br J Haematol 2020; 190: 27-8.
- Dai X. ABO blood group predisposes to COVID-19 severity and cardiovascular disease. Eur J Prev Cardiol 2020; 27: 1436-7.
- Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-9.
Abstract
References
- World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. http: //www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
- Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9: 548-53.
- Jing W, Zhao S, Liu J, Liu M. ABO blood groups and hepatitis B virus infection: a systematic review and meta-analysis. BMJ Open 2020; 10: e034114.
- Franchini M, Favaloro EJ, Targher G, Lippi G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci 2012; 49: 137-49.
- Ibrahim-Kosta M, Bailly P, Silvy M, et al. ABO blood group, glycosyltransferase activity and risk of venous thromboembolism. Thromb Res 2020; 193: 31-5.
- Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.
- Dunne E, Qi QM, Shaqfeh ES, et al. Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood 2019; 133: 1371-7.
- Latz CA, DeCarlo C, Boitano L, et al. Blood type and outcomes in patients with COVID-19. Ann Hematol 2020; 99: 2113-8.
- Göker H, Aladağ Karakulak E, Demiroğlu H, et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci 2020; 50: 679-83.
- Aktimur SH, Sen A, Yazicioglu B, Gunes AK, Genc S. The assessment of the relationship between ABO blood groups and Covid-19 infection. UHOD - Int J Hematol Oncol 2020; 30: 121-5.
- Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun 2020; 11: 5761.
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, https: //apps.who.int/iris/handle/10665/330854 (Accessed on January 25, 2020).
- Ding X, Yu Y, Lu B, et al. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019. Clin Chem Lab Med 2020; 58: 1365-71
- Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus 2021; 19: 317-26.
- Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO blood types and COVID-19: spurious, anecdotal, or truly important relationships? a reasoned review of available data. Viruses 2021; 13: 160.
- Wu BB, Gu DZ, Yu JN, Yang J, Shen WQ. Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis. Infect Genet Evol 2020; 84: 104485.
- Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev 2021; 48: 100785.
- Domènech-Montoliu S, Puig-Barberà J, Pac-Sa MR, et al. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. Int J Environ Res Public Health 2021; 18: 10039.
- Ray JG, Schull MJ, Vermeulen MJ, Park AL. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study. Ann Intern Med 2021; 174: 308-15.
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844-7.
- Fogarty H, Townsend L, Ni Cheallaigh C, et al. More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol 2020; 189: 1060-1.
- McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2: e437-e45.
- Cooling L. Blood groups in infection and host susceptibility. Clin Microbiol Rev 2015; 28: 801-70.
- Guillon P, Clément M, Sébille V, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 2008; 18: 1085-93.
- Cheng Y, Cheng G, Chui CH, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005; 293: 1450-1.
- O'Sullivan JM, Ward S, Fogarty H, O'Donnell JS. More on 'Association between ABO blood groups and risk of SARS-CoV-2 pneumonia'. Br J Haematol 2020; 190: 27-8.
- Dai X. ABO blood group predisposes to COVID-19 severity and cardiovascular disease. Eur J Prev Cardiol 2020; 27: 1436-7.
- Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-9.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Original Article |
| Authors | |
| Publication Date | March 15, 2022 |
| Published in Issue | Year 2022 Volume: 5 Issue: 2 |
Cite
Cited By
The effect of malignancy on prognosis in ICU patients with COVID-19
Anatolian Current Medical Journal
https://doi.org/10.38053/acmj.1117598
Fear of COVID-19: reflections on disease severity, sleep and anxiety in fibromyalgia patients
Journal of Health Sciences and Medicine
https://doi.org/10.32322/jhsm.1089198
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.